#OTC Markets Firm | Explore Tumblr Posts and Blogs

cking398 · 4 days

Text

CHAPTER 4: Best Broker : 1996-2003 My life had gone to plan I thought. By the year 2000, I was 27 and my own boss, respected by all my clients and starting to make some real money.

By 2003 I was not so sure. I had come to Asia seeking wealth and here I was, rolling in it. I had the pad and, I thought, the girl. Problem was I was depressed, underneath, I hid it, but my life had become a continuous nightmare. The job was getting to me. This one client especially. I had proof this guy tried to take me down. He was just a jealous prick. Got bullied at School, for sure. He did not attack me physically, but he had attacked my only baby up until that time. My baby was my business. Funny thing is this guy works now at the firm I created with my partners back in 2010 De Riva HK ltd. I named it like that because the name contains the first 6 letters of the products we were broking; derivatives and because Da River card in texas hold’em decides the game and this company was going to be my last play in finance.

To most of you, saying equity derivatives probably makes as much sense as saying gobble-di-gook. Nothing. Indeed to most people in finance, derivatives remain incomprehensible. Futures are simple derivatives. They can be based on a stock, a stock index, a commodity, a currency or an interest rate. They follow the price of the underlying instrument, for example if Oil goes up by 5 percent the price of the futures based on that product should go up by a similar amount. You can short them, sell them hoping they go down, as easily as you can buy them, I brokered these which just involved placing orders on the exchange. Options are less liquid than futures on indices and have wider prices (the bid offer spread is wider), so banks that need to do size generally use a broker. Options, give the right to the buyer to purchase a particular financial instrument at a particular price for a stated period of time. I was principally a broker specialising in exchanged traded listed options in Asia, I also did futures and I brokered the odd OTC trade.

There is a widely used equation to price these instruments known as Black and Scholes. The equation is brilliant but ultimately flawed. The equation does not take into account "Black Swans" as famously talked about by Mr. Taleb in his book of the same name. The two Professors who came up with this equation Mr. Black and Mr. Scholes eventually won the Nobel prize for the equation that they came up with in the 1970s. It had revolutionised finance. In the 1990s they created a fund called Long Term Capital Management with the help of friends. Long Term Capital Management ended up to be a fund which became very short term turning the Long Term in the funds name on its head. The fund famously blew up and had to be rescued by the federal reserve in 1998 after Russia defaulted on its debt. From inception to destruction it did not even last 5 years. In those five years, the managers became extremely rich while their shareholders were less fortunate. Brilliant men, clearly, but flawed, like the rest of us.

Anyway I did not care about the formula. I was a broker, it was important to know where volatility was sometimes but not essential. I was the guy who put prices together. Say a bank wants to buy Hang Seng Index options (the equivalent in America would be options on the SP500, the Hang Seng is the Hong Kong equivalent), they call me, I ask a market maker which are generally small firms that make bids and offers for banks and the market in general. In return they get a preferential fee schedule from the exchange . Now I have a buy price and a sell price. My job is to put them together and trade. I would go back to the trader at the bank which asked me for the price and he would give me a bid or an offer if he wanted to sell the option. I would try and find a counterparty for the other side. Everyone knew where the fair value was because traders were basically working off the same formula. I would make a lot of calls. I was the broker with the best contacts in the market. This was important because I could probably get the best price for the guy or gal who had asked me for the price on the option. That’s why traders dealt through me. To be a good options broker, you had to be a good guy. People could always take their business elsewhere.

I was basically the best listed options broker on one exchange, in one country in the world, China. I was an IBD. Inter-Bank dealer. I had no retail clients, only institutional. Karim had taught me the job at Fimat but when he left for Japan for a similar position on the Japanese market, I had single handedly opened all but three of the accounts for KGI Asia Ltd. These included JP Morgan, Lehman Brothers, Morgan Stanley, Goldman Sachs, HSBC, UBS, Merrill Lynch, Societe Generale, BNP, Bear Stearns amongst others. There were three agreements already signed when I joined KGI Asia ltd. A broker called Dun Lee had begun opening the accounts until he decided his best bet was to start an internet shop in 1999 with his mates.

I opened the rest 40+, this included around 5 market makers and small funds. I managed to do this by always being forthright with clients, sure there were tricks of the trade that I used when broking, but on the whole, people passed orders through me because I was the most trustworthy and best broker in Hong Kong. I had done this through a combination of consistency, charm and humbleness. My British School of Brussels education had primed me to be good at this kind of work. The school where I had grown up had over 100 nationalities among its students. I had no racist bone in my body.

I knew I was the best not because I said so, but because clients regularly told me and they voted with their order volume. I knew the game, It was a game of respect, this was the game of equity derivatives broking, the same 'game' I had played on the street and in School. Being a straight shooter. Not always straight with the law when I was growing up, but straight with my friends.

People talk in finance and they obviously liked my story. Whenever a new trader came to town I would invite them for lunch, drinks or dinner. Normally lunch. I would always try and make the first meeting one on one. People are different in groups; They watch their words more carefully. One on one you can really get a sense of a person. People tended to like me.

When I was starting out on the Hong Kong Options desk at Fimat, it was 1996 and they gave me one real client. I spoke to the market makers. But these weren’t real clients as they generally did not cross the bid offer spreads, the other brokers all guarded their clients, the banks, from each other like precious cargo. I was 24. It was the middle of the Asian financial crisis. This guy who worked for Chase Manhattan bank was a prick, an English prick. Now I think of him, he reminds me of David Brent from ‘The Office’ (UK office series) but with none of the humanity. Anyway, he rarely traded, no one wanted him as a client. So they gave him to me. This one day, we had 100 lots on the offer on some option product. It was a regular sized order the problem was everyone wanted to buy. In this case it was normal practice to split the size up and not give it all to the first one who said buy them. We split the order into 4, the smallest size we allotted was 25 on trades. Anyway he wanted to buy, as did about 8 other clients. I managed to secure 25 for this guy, from the 4 batches we were giving out. This bloke turns round and says “give them to your grandmother”. He was insulted by the size he was allotted. Anyway, without a moment's hesitation, I said to him “if you mention my grandmother again I will cut your line”. At the time, as I mentioned, I had one client, one line. He tried to laugh it off. I wasn’t laughing. After that story made the round of the market. I was kind of a hero. Apparently, no one liked him. Later, he was leaving Hong Kong to go to work in London and tried to sell me his car, a Saab. I did not have a parking space and did not make enough to justify owning a car in Hong Kong. I met him by chance in a club in Hong Kong a week later, just before he was about to leave. He goes into this story about how he really got one over on some guy who bought his car cause it had all these malfunctions. As I said, he was a prick, he probably didn’t even remember trying to sell it to me.

By the end of 1998 the volume really started to die on the listed options market. The Asian financial crisis was in full swing by this time. The authorities had tightened the rules on warrant trading which was where most of the order flow from the banks originated. Volume collapsed and the good brokers on the desk had moved on. There was only Karim left. He seemed more interested in playing computer games than broking. He let me talk to his clients which was basically the whole market. He would go to lunch with the clients, I would tag along. I got to know all of them. He got an offer from a Japanese IBD and moved to Tokyo. By then I was the best broker in town, I had been on the desk for 5 years and knew the game inside out. David Friedland (Sherphardic Jew), a top man at interactivebrokers in Hong Kong which had a market making arm, and was a friend, told me about a possible deal at KGI, a Taiwanese bank. It was commission only, I had to put a deposit down to insure against my losses. I did the maths. Even if I did 50 percent of current volume, I would make more than the shitty money Fimat was paying me and I would be my own de facto boss. I jumped all over it.

When my boss at Fimat found out I was leaving, he asked me what deal they offered, he said he wanted to see if maybe he could match it. The deal basically let me keep 70 percent of what I made, it was one of the best deals for brokers in equity derivatives in the world. Still now, the best brokers only get 50 percent and they have all these charges added to them (for example, rent of their seat, telephone costs, back office costs etc). I gave him a chance, I told him what KGI was offering, he said he could not match it and I left. A couple of weeks later I found out he was going round Hong Kong telling people he had planned to make me a star. What a buffoon. I was already a star. Before moving on, when Karim was sick or took the day off I had to sit next to my boss on the dealing desk. There was an empty seat between us. I will always remember when we closed a deal and he spoke to one client and I had the opposing client on the other side. He would yell at me. Instead of saying calmly I will buy them from you or just simply done. He would yell it, like we were on the floor of the exchange or in a movie or something. When we had company get-togethers, he would have it at his exclusive country club. These so called get togethers pissed me off. He introduced his wife to me three times and every time he would tell me her uncle was the CEO of BNP Paribas. Awkward for me, I can only imagine what she thought. Poor woman. She did not have much of a personality, if truth be told. I only had one-on-one lunch with him twice and both times this prick would talk about money and only money. That’s the only thing he ever talked about. Talk about a boring asshole. A few years after I left. Rumour had it that they found some discrepancy in Fimat’s accounting. He was fired. Of course, they never took him to the authorities, bad publicity. A lot of that goes on in finance.

In the markets my day would really start when traders asked for a market on an options structure. Around 10am, when the stock market opened, we would check prices of various options structures from market makers or when it turned electronic, more often than not, straight from the screen and show them around in the hope of getting a bank to show some interest. If traders showed an interest straight from the off in a particular structure we would not have to show random markets around. This was better but it was slow going from 1998-2000, so more often than not we had to check structures we had recently traded previously or ‘invent’ structures to check we thought people would have an interest in. Anyway, barring orders coming in this is what I did at Fimat. I was also responsible for covering the Japanese and Taiwanese futures markets. Japan would open at 8am Hong Kong time. This was generally orders coming from the Fimat london office. So from 8am to 9:45am when the HK market opened I generally read a book or the South China Morning Post, the most prominent English newspaper in Hong Kong. There was a young reporter there who would call me up to find out about market action. When he first did it I was only 24. It gave me a kick to see my name in the paper. I would say ridiculous things and they would appear in print the next day. Like he asked me why the market went up and I would say there were more buyers than sellers. We went out together a few times, a young Australian guy. Good bloke. My old boss, not the one from the previous paragraph, put a stop to me quoting for the newspapers after he got wind of it. When my boss guy arrived from the Fimat Tokyo office, the guy from the previous paragraph, he would bother me literally every morning. Standing next to me and saying “well” (the french equivalent, “alors”), so this ‘tool’ expected me to turn round and entertain him as if I was some kind of lackey. Something else that pissed me off about him. He would not bother Karim as Karim was a lebanese christian and they did not get along. He was a French Ashkenazi jew who probably followed the Talmud. Not that I have anything against jews in general but there seemed to be a lot of them in finance in Hong Kong and most seemed to be of the Talmudic variety (The Talmud is a truly disgusting document which refers to Gentiles as pigs). As far as I could tell at all the French banks, the bosses in equity derivatives were all French jews. Weird.

There are a couple of moments that stood out in the first couple of months after I had joined KGI. It was the end of the year 2000 and the market had crashed again, this time with the internet bubble. Volumes had fallen. Even so, in my first month I made 12,000 USD with only 75 percent of regular accounts open and this included a big loss on my error account.

The first moment that stood out was involving one of my best friends at the time and, who also was one of my best clients, worked at Bear Stearns, an American lady called Susan Chan, she headed a group of traders out of Tokyo. She placed orders on the Hang Seng futures market through me. KGI had given me a direct link to the exchange. I only had 50k USD (400k HKD) to guarantee my trades, this represented most of the money I had been able to save after 5 years at Fimat. This was the insurance money KGI requested to cover any losses I might produce. I had never had a loss of more than 10k USD on any brokered deal through my five years at Fimat so I thought that 50k USD was more than enough to cover any losses I might have over any given month. One day in the summer of 2000, Susan placed an order to buy 100 Hang Seng futures contracts at 11,000. The market was trading a couple of hundred points higher. Not anticipating any other orders (it was quiet), I had already checked a few markets, no interest. I leaned back and started reading the paper. The market was electronic, one window showed my open orders, the other filled/executed orders. After five to ten minutes of reading, I glanced at the screen to see what the markets were doing. 11,060 they were approaching my buy level. I looked at my open orders window, nothing. I looked at my filled orders screen, fuck. I had inputted the order wrong. I had bought 100 at 11,100 instead of 11,000. In the three years that the market had been electronic I had never made a mistake of this magnitude. I calculated my loss quickly 40 points x 50 HKD per point x 100 contracts, 200k HKD (around 25k USD gone in a few minutes), half of what I had managed to accumulate in 5 years. The market was moving fast and it was illiquid. If I sold my position at the market it could easily drop another 40 points wiping out the entirety of my 5 years of savings. I considered calling Susan to see if she would take them but then I would look like a fool. I sold 20 at 11,060, the market rose I sold another 20 at 11,080, it rose again, I sold the balance of 60 at 11100 where I had bought them. My loss ended up being only 30 points on 40 contracts representing 60k HKD (or around 8k USD). The funny thing is that it never touched 11,000 after it went back up to 11,100 it kept on going. It finished the day up a 1000 points. If I had not checked my screen for another 5 minutes I would have been in the money big time. The market ended up having one of the biggest rallies of the year that day 11,060 was the low. Weird. I was proud of myself though. I had done the right thing. I had shaved a third off my net earnings for the first month but I had survived. I was in the game for the long term and for that, survival was key. Also, I had not gone to Susan telling her about my error and asking her to take the futures off my hands like a beggar. I had swallowed the loss and could hold my head high. Years later, after she was no longer a client of mine, I told her about that day. She turned to me and said “why didn’t you call me, I would have taken them” “honour” I said. This was true but I had also considered that maybe her impression of me would have changed if I had called her for her help. You never know how people will act if you ask them for favours. Or how they will view you afterwards. Also, if they refuse, they might feel guilty about it and that is not conducive to a good business relationship.

The other moment involved a trade I placed on the exchange literally in the last second of trading. I think it was in the second month I was there. A bit of background first. They were straight shooters at the Taiwanese bank and I liked my bosses and the people there. Never cheated me on the original deal I made with them. I was the only white guy in a dealing room full of Chinese. The office was open plan. I sat in the corner of a massive trading floor. Maybe 300 retail brokers worked there, but I was the only institutional broker. This also meant I had one of the only phones systems with direct lines to my most important clients. They could call me by pressing a button and it would come over the speakers. I could do the same to them. They put me close to the senior traders at the bank so they could watch me. I was the only white guy working at KGI but they never made me feel uncomfortable. Most of the other brokers dealt only with retail clients. The only other foreigner was a Japanese guy who made a lot of money apparently. He had Japanese clients and he had set up some sort of legal tax dodge for his rich Japanese clients. Not quite sure how it worked, his English was bad and we were on opposite sides of the trading floor. Anyway, back in the day the stock exchange closed at 4pm, so the floor was deadly quiet at that time, including our trading floor. The other brokers would be doing their end of day paperwork. My market, the options and futures market only closed at 4:15pm. I had been negotiating a deal for about 15 minutes after a furious day of broking options. At 4:14pm I closed the deal verbally but I still had to post it on the exchange, doing so the next day was complicated and would have led to a lot of phone calls between my clients and I, with explanations and so on. I typed furiously into the exchange’s computer, I had to adjust the delta, the details aren’t important. Anyway, I clicked on the send button not having looked at the time but knowing I had maybe seconds left. I looked over at the executed/filled window. It had gone through. I looked at the exchange ticker, 4:15:00 I was the last trade on the exchange. I had never been the last trade on the exchange. I stood up, not thinking about where I was. I yelled “Ya motherfucker” real loud, pumping the air with my fist, I scanned the room and saw three hundred heads and eyes turned my way. Shit, I quickly ducked. Embarrassed but still happy.

#salvation #jesus christ #jesusreborn #jesusgloriouscoming #christisking #olympics 2024 #2024 olympics #candaceowens #tucker carlson #trump 2024

1 note · View note

coineagle · 8 days

Text

Crypto Daily Rundown: Bitcoin, Solana, and Others Make Headlines!

Key Points

Bitcoin [BTC] rebounded to $58k following slower August inflation data.

Alameda/FTX unstaked over $23 million SOL as repayment for victims approaches.

The US CPI (Consumer Price Index) increased 0.2% last month, meeting analysts’ predictions.

The core CPI, however, was slightly higher at 0.3%, above the anticipated 0.2%.

This resulted in Bitcoin‘s price falling to $55.5k.

Investors’ Risk-Off Mode

Before the release of the CPI data, investors were in risk-off mode, leading to $750 million outflows from exchanges on 10 September.

However, the world’s largest digital asset recovered and was valued at $58k.

Joshua Kang, Head of Trading at Mozaik Capital, commented on the post-CPI movement and the market’s focus on the upcoming FOMC (Federal Open Market Committee) meeting.

Following the slower CPI, the market appeared to be pricing in an 85% likelihood of a 25-basis-point Fed interest rate cut at the next FOMC meeting.

QCP Capital, a crypto trading firm, reported increased demand for Bitcoin and a bullish outlook for Q4 post-CPI data.

Alameda/FTX Unstakes $23.75M SOL

A wallet linked to Alameda/FTX redeemed 177,693 SOL from Solana PoS staking, with $951 million SOL still staked.

This occurred as FTX’s repayment for victims neared.

Despite FTX reportedly selling most of its SOL through OTC (over-the-counter) markets, market analyst EmberCN suggested that the unstaked SOL could soon hit central exchanges.

If this happens, it could exert downward pressure on SOL.

At press time, the altcoin was trading at $134, slightly above its yearly support of $128.

Swift announced support for regulated digital and real-world tokenized asset transfers as part of its “global interoperability strategy.”

This follows a series of blockchain payment experiments last year involving Chainlink, Ethereum, and several banks, including BNY Mellon.

The move will enable buyers to settle and exchange tokenized assets in real time through the Swift network.

0 notes

recentlyheardcom · 9 days

Text

The Superior OTC Markets Investor Relations Firm

Creator William Kimbler Revealed July 9, 2021 Phrase rely 685 OTC MARKETS INVESTOR RELATIONS FIRM ALL YOU NEED TO KNOW ABOUT OTC MARKET Are you questioning how one can minimize to the chase? As an alternative of paying a lot to a center social gathering, what for those who might promote shares OTC? The answer to this downside is at OTC Markets Investor Relations Agency. It hyperlinks…

0 notes

kathansky · 11 days

Text

E-pharmacy Market: Size, Share & Growth | 2024-2031

E-pharmacy Market Overview: A lot of factors, such as geographic growth, segmentation, and market size by value and volume, are taken into account in the SkyQuest Technology Group research to provide a full and accurate analysis of the global E-pharmacy market. This outstanding research study was created specifically to provide the most latest data on significant aspects of the global E-pharmacy Industry. Numerous market estimates are provided in the analysis, including those for market size, output, revenue, consumption, CAGR, gross margin, price, and other critical factors. The best primary and secondary research methods and tools on the E-pharmacy market were used to build it. Numerous research studies are included in it, including ones on pricing analysis, production and consumption analysis, company profile, and manufacturing cost analysis. The competitive environment is a crucial element that every key factor needs to be aware of. The study explains the market's competitive landscape so that readers may gauge the degree of both domestic and global rivalry. Additionally, market researchers have provided summaries of each significant firm in the global E-pharmacy industry, taking into consideration crucial elements including operational areas, production, and product portfolio. When analyzing the organizations in the study, significant factors including business size, market share, market growth, revenue, production volume, and profitability are also taken into account. The study report uses both qualitative and quantitative data to offer a thorough view of the market. It examines and forecasts the global market in a number of critical industries. The research provides a thorough overview of the industry by segmenting the E-pharmacy market into groups based on application, end-user, and location. A thorough research of each market segment was conducted, taking into consideration current and upcoming market trends.

E-pharmacy Market size was valued at USD 52 billion in 2022 and is poised to grow from USD 62.14 billion in 2023 to USD 308.8 billion by 2031, growing at a CAGR of 19.5% in the forecast period (2024-2031).

Chance to get a free sample @ https://www.skyquestt.com/sample-request/e-pharmacy-market Detailed Segmentation and Classification of the report (Market Size and Forecast - 2031, Y-o-Y growth rate, and CAGR): The E-pharmacy Market can be segmented based on several factors, including product type, application, end-user, and distribution channel. Understanding these segments is crucial for companies looking to target specific markets and tailor their offerings to meet consumer needs.

Drug

Prescription Drugs, Over-the-Counter (OTC)

Product Type

Skin Care, Dental, Cold, Flu, Vitamins, Weight Loss, Others

Get your Customized report @ https://www.skyquestt.com/speak-with-analyst/e-pharmacy-market

Following are the players analyzed in the report:

DocMorris

Medlife International Pvt. Ltd.

Walmart stores

CVS Health Corporation

Walgreen Co. (Walgreens Boots Alliance, Inc.)

Rite Aid Corporation

Amazon.com, Inc.

The Kroger Co.

Rowlands Pharmacy

Netmeds Marketplace Limited

1mg Technologies Private Limited

Walgreens Boots Alliance, Inc.

Chemist Warehouse Group

Apollo Pharmacy

LloydsPharmacy Limited

Zur Rose Group AG

Walgreens Boots Alliance, Inc.

SHOP APOTHEKE EUROPE N.V.

SANICARE Group

Phoenix Group Holdings

Motives for purchasing this report- - A full understanding of customer experiences, upcoming trends, and growth drivers may be obtained by market category analysis. - E-pharmacy Market participants will be able to quickly decide on their course of action in order to achieve a competitive advantage thanks to the essential information provided in this area. The factors affecting the sales prospect are carefully examined by SkyQuest Technology Group across several important categories. - Analysing market categories can provide detailed insights into consumer experiences, upcoming trends, and growth-promoting factors. A thorough analysis of market manufacturing trends is a crucial component of the study. -These observations offer crucial information on the ways in which market participants are reacting to the most recent developments that are oversaturating the market. -An in-depth analysis of the numerous organic

Buy your full Market Report now: https://www.skyquestt.com/buy-now/e-pharmacy-market FAQs:

1. What are the main vendors' points of strength and weakness?

2. What are the primary business plans of the leading important players for the near future?

3. What will the market size and growth rate be for E-pharmacy in the upcoming year?

4. Which prevailing global trends are affecting the E-pharmacy market shares of the leading regions? What effect does Covid19 have on the Industry right now?

#healthcare #health & fitness #health and wellness #healthylifestyle #health #wellness

0 notes

altiusinvestech · 25 days

Text

Boat Unlisted Shares: Potential Benefits and Risks for Early Investors

Introduction

Investing in unlisted shares becomes an intriguing option for investors who want to capitalize on high-growth companies before going public. BoAt has drawn considerable attention with its strong market presence and rapidly evolving brand equity. BoAt gives investment opportunities in unlisted shares. However, like all investments, this also comes with risks and not just benefits. Let us help you make an informed decision through this blog.

Understanding Unlisted Shares

Unlisted shares are the equity shares of a company that are not listed on any stock exchange. The shares are typically traded OTC or through private placements, which makes them less liquid and accessible in comparison to listed shares. Investments in unlisted shares usually attract seasoned investors, private equity firms, as well as venture capitalists who intend to enter early in the growth cycle of the company.

The price of boat unlisted shares is Rs 1415. You can buy the shares from Altius Investech.

Potential Benefits of Investing in BoAt’s unlisted shares

Early Entry Advantage

Investing in unlisted shares of a company like Boat allows investors to enter at an early stage, potentially reaping substantial returns once the company goes public. If Boat decides to launch an Initial Public Offering or IPO in the future, the valuation could be significantly higher than the current unlisted share price, offering a lucrative exit opportunity.

High Potential for Growth

boAt’s rapid expansion and brand recognition suggest that the company is on a high-growth trajectory. boAt Earns Rs.2,873 cr in Revenue in FY22. By investing in its unlisted shares, investors can benefit from this growth. The Indian consumer electronics market is poised for continued expansion, and boAt’s strong positioning within this market could translate into robust financial performance.

Long-term value creation

Companies like Boat that are in the growth phase often reinvest profits into the business to expand operations, develop new products, and increase market share. Early investors in unlisted shares can potentially benefit from this long-term value creation as the company scales up and enhances its profitability.

Access to exclusive investment opportunities

Investing in unlisted shares is not as straightforward as purchasing listed stocks. It often requires networking, knowledge, and sometimes, significant capital. By investing in unlisted shares, investors gain access to exclusive opportunities that are not available to the general public, positioning themselves to potentially benefit from the company’s future success.

Diversification

Unlisted shares often move independently of the stock market, offering a hedge against market volatility. This can be particularly beneficial during market downturns, as unlisted shares are less susceptible to immediate market sentiment.

Risks Associated with Investing in BoAt’s Unlisted Shares

Lack of Liquidity

Finding a buyer can be challenging since these shares are not traded on a public exchange. Investors may have to hold onto these shares for an extended period before they can sell them, which can be a drawback if the need for capital arises unexpectedly.

Challenges of Valuation

Unlisted shares do not have a readily available market price. Determining the fair value of unlisted shares can be complex and subjective, often relying on limited financial information and market speculation. This uncertainty can lead to either overvaluation or undervaluation of the shares.

Information Asymmetry

Shareholders with unlisted shares typically have less information about their company as compared to public companies. This could result in a greater risk of making ill-informed investment decisions. Investors should rely heavily on the transparency and credibility of the management.

Uncertainty about IPO

Even if an IPO is planned, it may be delayed or canceled due to market conditions or strategic decisions by the company. This uncertainty can affect the potential return on investment. While the prospect of a future IPO can be a major reason to invest in unlisted shares, there can be no guarantee for boAt to go public.

Business and Market Risks

BoAt is susceptible to market risk, including shifting customer preferences, competitive pressures, and economic slowdowns, like any other company. As a booming business, Boat faces the risk of expansion operations inefficiencies, as well as issues with management that may impact its financial performance, and consequently their value. non-listed shares.

Regulatory Risks

Unlisted shares are subject to less stringent regulatory oversight compared to listed companies. This can expose investors to legal risks if the company fails to comply with necessary regulations or faces litigation. Additionally, changes in regulations affecting unlisted companies could impact the value and tradability of the shares.

Final Thoughts

Investors interested in Boat’s unlisted shares should conduct thorough due diligence, consider their risk tolerance, and consult financial advisors to make informed decisions. While the rewards can be significant, they come with considerable risks that must be carefully weighed.

#boat unlisted shares #altiusinvestech

0 notes

delistedshares · 1 month

Text

Reliance Retail Unlisted Shares: A Guide to Investing

Investing in unlisted shares can be a strategic move for savvy investors looking to gain exposure to high-growth companies before they go public. One prominent player in this space is Reliance Retail, a subsidiary of Reliance Industries and one of India's largest retail chains. This guide will help you understand the potential of investing in Reliance Retail unlisted shares, including how to track the Reliance Retail unlisted share price and make informed investment decisions.

Understanding Reliance Retail Unlisted Shares

Reliance Retail is a major player in India's retail sector, with a vast network of stores across various formats, including grocery, fashion, and electronics. As an unlisted entity, its shares are not available on public stock exchanges. Instead, they are traded privately, often through over-the-counter (OTC) platforms or direct transactions between buyers and sellers.

Why Invest in Reliance Retail Unlisted Shares?

Growth Potential: Reliance Retail has shown impressive growth over the years. Investing in its unlisted shares allows you to tap into the company's future growth potential before it becomes publicly traded.

Diversification: Adding Reliance Retail unlisted shares to your portfolio can diversify your investments, especially if you're looking to gain exposure to the retail sector.

Early Access: Buying Reliance Retail unlisted shares provides an opportunity to invest in a leading company at a potentially lower price before it lists on the stock exchange.

Tracking the Reliance Retail Unlisted Share Price

Since Reliance Retail shares are unlisted, their prices can be less transparent than those of listed stocks. To track the Reliance Retail unlisted share price, consider the following methods:

Private Marketplaces: Unlisted shares are often traded on private marketplaces or OTC platforms. These platforms may provide current pricing and recent transaction data.

Brokerage Firms: Some brokerage firms specialize in unlisted shares and can provide up-to-date information on the Reliance Retail unlisted share price.

Financial News and Reports: Keep an eye on financial news and reports that may offer insights into the company's performance and any potential changes in its share price.

How to Invest in Reliance Retail Unlisted Shares

Research: Thoroughly research Reliance Retail’s financial health, business model, and growth prospects. Understanding the company's fundamentals is crucial before making any investment.

Find a Seller: Since these shares are unlisted, you’ll need to find a seller, which could be through private transactions or specialized brokers dealing in unlisted shares.

Valuation: Determine the fair value of the shares based on current market conditions and the Reliance Retail unlisted share price. Ensure you are paying a reasonable price.

Legal and Regulatory Aspects: Ensure that all transactions comply with legal and regulatory requirements. Consult with legal experts if necessary.

Risks and Considerations

Investing in unlisted shares carries its own set of risks:

Liquidity: Unlisted shares may be harder to sell quickly compared to listed stocks.

Transparency: Information about unlisted companies may not be as readily available as it is for publicly traded companies.

Valuation: Valuing unlisted shares can be challenging, and prices may vary significantly based on supply and demand.

Conclusion

Investing in Reliance Retail unlisted shares offers the potential for significant returns, especially given the company's strong market position and growth prospects. However, it's essential to stay informed about the Reliance Retail unlisted share price and conduct thorough research before making any investment decisions. By understanding the dynamics of unlisted shares and following a strategic approach, you can position yourself to benefit from one of India’s leading retail giants.

For the latest updates and information, regularly check private marketplaces, consult with financial advisors, and keep abreast of industry news.

#Reliance Retail unlisted share price #relianceindustries #delisted stocks

0 notes

todaynftnews · 1 month

Text

Cumberland, a subsidiary of DRW Holdings specializing in over-the-counter (OTC) trading, has actively participated in the crypto market by receiving and transferring a substantial amount of USDT. Recently, the firm received 95 million USDT from Tether’s treasury and moved it to several major cryptocurrency exchanges, including Coinbase, Kraken, and OKX.

#TodayNFTnews #NFTs #NFTmarket #NFTnews #Blockchain #Crypto

0 notes

insights10-marketing · 2 months

Text

A new level has been unlocked in the data-driven world! 7th Nov 2022 marked the go-live of the hashtag#Insights10 website v2.0! Insights10, a sister-concern of Healthark Insights and the go-to website for your business research needs, started in January 2021 as a collection of a few market reports. It is, today, a carefully curated repository of over 35,000+ titles, spanning across a multitude of domains in all regions of the world. hashtag#Insights10 a market research firm that specializes in healthcare and allied industries such as pharmaceuticals, diseases/therapies, medical devices, digital health, healthcare services, OTC and nutraceuticals, etc. and provides syndicated and customized research reports in these domains. Congratulations and thanks to the Insights10 team for achieving this milestone! For more information, check out our website https://www.insights10.com/

#dataandinsights #market analysis #market forecast #market research #market insights #market report #healthcare #pharmaceutical #Lifesciencemarketresearch #Marketresearch #medicaldevices #digitalhealth

0 notes

blockinsider · 2 months

Text

Potential Bitcoin Rebound Signaled by Decrease of 670K Holders, Says Santiment

Key Points

According to Santiment, the significant decrease in Bitcoin wallet addresses could indicate a potential market rebound.

Despite the decline in wallet addresses, Bitcoin’s spot markets have shown resilience with prices hovering around $64,800.

Santiment, an on-chain analytics platform, has reported a significant decrease in the number of Bitcoin wallet addresses holding BTC. This could suggest a potential market rebound. On July 18, it was reported that there had been a reduction of 672,510 Bitcoin holders with a balance of more than zero BTC.

Market Rebound Possibilities

Santiment has suggested that some traders might believe that the market peak in March was the highest point for 2024. However, the firm has noted that large sell-offs are usually followed by market recoveries. They stated, “When we observe such mass liquidations, the likelihood of a rebound increases.”

This trend has been observed since Bitcoin last reached over $70,000 in early June. Although Bitcoin prices have recovered to around $65,000 recently, the number of BTC holders has not shown a significant rebound yet, which typically follows spot market recoveries by several weeks.

Market Indicators and Institutional Activity

Data from Glassnode shows that at the current price, 89.43% of Bitcoin’s supply is in profit, down by 6.5% from mid-June when BTC was near $70,000. However, other indicators suggest a positive outlook. Ki Young Ju, the founder of CryptoQuant, pointed out that over-the-counter (OTC) markets are currently overshadowing centralized exchanges, which indicates strong institutional accumulation.

Ju reported that whale wallets, including those holding more than a thousand coins, have added 1.45 million BTC this year, bringing their total to 1.8 million BTC, about 9% of the circulating supply. He also highlighted that the weekly inflow to these whale entities is now higher than the total for the entire year of 2021.

Trading Volumes and Broader Market Trends

Despite the decline in wallet addresses, Bitcoin spot markets have shown resilience, with prices hovering around $64,800 at the time of writing. Trading volumes on centralized crypto exchanges dropped by 21.8% in June, marking the third consecutive month of declines.

According to a report by CCData on July 17, the combined spot and derivatives volume across all centralized exchanges stood at $4.2 trillion in June, a 53% drop from the $9 trillion peak in March. Additionally, open interest across crypto derivatives exchanges fell by 9.7% due to liquidations triggered by a sharp drop in Bitcoin and other crypto assets.

Bitcoin’s Future

In a recent update, popular crypto analyst Michaël van de Poppe shared an optimistic outlook for Bitcoin’s performance in the latter half of 2024. He emphasized that increasing inflows from exchange-traded funds (ETFs) could drive Bitcoin price higher.

Van de Poppe noted that Bitcoin saw significant net inflows from ETFs, exceeding $400 million last month, which indicates strong institutional interest and stability around the $65,000 mark. He suggested that Bitcoin’s price could potentially reach $100,000 in the near future, supported by ongoing institutional investments.

0 notes

coinguitar · 2 months

Text

Germany Dumps All Bitcoin: Could This Impact the Crypto Market?

On July 12th, according to data from blockchain analytics firm Arkham Intelligence, the German government completed the sale of its entire Bitcoin stash. The final transaction involved sending 3,846 BTC to “Flow Traders and 139Po,” which Arkham identified as “likely institutional deposit/OTC service.” This sale marked the culmination of weeks of selling activity, with the German government…

#bitcoin #blockchain #Crypto #crypto news #news

0 notes

wellnessweb · 3 months

Text

Understanding the E-Pharmacy Market Size in Key Regions

The E-Pharmacy Market size was estimated at USD 73.38 billion in 2023 and is expected to reach USD 321.89 billion by 2031 with a growing CAGR of 20.3% during the forecast period of 2024-2031.The e-pharmacy market is rapidly transforming the healthcare landscape by leveraging digital platforms to enhance accessibility, affordability, and convenience for consumers worldwide. This sector, driven by the increasing penetration of smartphones and internet connectivity, enables patients to order prescription and over-the-counter medications online, often at competitive prices. E-pharmacies offer significant benefits, such as discreet transactions, comprehensive drug information, and automated refill reminders, which improve medication adherence.

Get Sample of This Report @ https://www.snsinsider.com/sample-request/3101

Market Scope & Overview

The scope, global demand, marketability, profitability, and potential of the industry are all extensively covered in the most recent market research report. The research report examines the market in depth and offers details on a variety of subjects, including market drivers, constraints, opportunities, and threats. The potential for growth at the international, regional, and industrial levels is examined by E Pharmacy Market research. The study also examines the consequences of the epidemic and offers suggestions for reducing market volatility.

Market Segmentation Analysis

By Drug type

Prescription drug

Over-the-counter drug (OTC)

COVID-19 Impact Analysis

A comprehensive risk analysis and business ideas for the target market were created over time. The market circumstances prior to and following COVID-19 are also contrasted in this study paper. The influence of the COVID-19 epidemic on the market was thoroughly examined by the E Pharmacy Market report.

Regional Outlook

In order to obtain qualitative and quantitative market data from internal and external sources, extensive multi-level research was first done. The plan also calls for the development of projections and overviews of regional markets for each category. During the E Pharmacy Market research, the total market size was calculated using both primary and secondary data.

Competitive Analysis

Genuine information can help investors make smarter financial choices. In order to assist companies in the E Pharmacy Market sector in making wiser decisions, the research's competition landscape section also includes the most recent information on recent partnerships, mergers, and acquisitions as well as key competitors' tactics.

Key Questions Answered in the E Pharmacy Market Report

What impact will COVID-19 have on your target market?

Which market considerations have recently influenced decisions the most?

What are the target market's opportunities, threats, and prospects for the future?

Conclusion

In order to provide a thorough picture of the industry and help businesses better appreciate the possibilities offered by the various regional regions, the research report examines the E Pharmacy Market .

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Glaucoma Therapeutics Market Trends

DNA Synthesis Market Trends

Genomics Services Market Trends

Immunomodulators Market Trends

Lymphoma Treatment Market Trends

0 notes

pipara · 3 months

Text

Demystifying PCAOB Audits for US Listings: Your Guide with a Leading PCAOB Firm in India

Public Company Accounting Oversight Board (PCAOB) audits are a crucial stepping stone for companies aiming to list on US stock exchanges or the OTC Markets. As a leading PCAOB firm, Pipara & Co LLP is here to guide you through the intricacies of PCAOB audits and how they can empower your US listing journey.

What is a PCAOB Firm?

The PCAOB is a non-profit organization established by the US Congress to oversee the audits of public companies. Essentially, a PCAOB firm is an auditing firm registered with the PCAOB, demonstrating its adherence to rigorous international auditing standards.

Why are PCAOB Audits Important for US Listings?

For companies considering a US listing, a PCAOB audit is not just an option, it's a necessity. Here's why:

Enhanced Credibility: A PCAOB audit signifies a higher level of financial scrutiny conducted according to internationally recognized standards. This bolsters investor confidence in the accuracy and transparency of your financial statements, making your company a more attractive investment proposition.

Improved Liquidity: Investors often prioritize companies with audited financials, especially those conducted by PCAOB firms. A PCAOB audit can potentially improve your stock's liquidity by attracting a wider investor base in the US market.

Smoother Uplisting: If you plan to uplist from the OTC Markets to a major exchange like NYSE or NASDAQ, a PCAOB audit is mandatory. By having a PCAOB audit in place from the outset, you avoid unnecessary delays and complications during the uplisting process.

Understanding PCAOB Requirements for Different US Listing Options:

The specific PCAOB requirements can vary depending on the type of US listing you pursue:

Major Stock Exchanges (NYSE, NASDAQ): All companies listed on major US exchanges must have their financial statements audited by a PCAOB-registered firm.

OTC Markets: The OTC Markets offer an alternative trading system for companies not yet listed on major exchanges. However, specific tiers within the OTC Markets have varying audit requirements:

OTCQX: Companies seeking to uplist to OTCQX must have current financial reporting with a national securities exchange or a banking or insurance regulator, often translating to audited financials prepared in accordance with US GAAP or IFRS (for International Reporting Companies).

OTCQB: This tier requires annual financial statements audited by a PCAOB firm in USA, prepared in accordance with US GAAP or IFRS.

OTC Pink: The most basic tier with minimal requirements. However, companies aiming to attract investors often choose to have their financials audited by a PCAOB firm for increased transparency.

Pipara & Co LLP: Your Trusted PCAOB Firm Partner

As a PCAOB-registered firm with a strong global presence, Pipara & Co LLP is your one-stop shop for navigating the complexities of PCAOB audits for US listings. Our team of experienced professionals possesses in-depth knowledge of both US GAAP and international accounting standards (IFRS), ensuring seamless compliance throughout the audit process.

Here's what sets Pipara & Co LLP apart:

Global Reach with Local Expertise: We leverage our experience serving clients across India, Dubai, and the USA to provide a comprehensive understanding of international financial landscapes.

Seamless Communication: Our dedicated team ensures clear and consistent communication throughout the audit process, keeping you informed and involved at every step.

Commitment to Quality: We prioritize delivering high-quality audits that meet the highest international standards, fostering investor confidence in your company.

Ready to Take the Next Step?

Contact Pipara & Co LLP today for a free consultation to discuss your specific US listing goals and how a PCAOB audit can pave the way for success. With our expertise and dedication, we will ensure a smooth and efficient audit process that empowers your company's journey towards a successful US listing.

#PCAOB audit #statutory audit applicability

0 notes

coineagle · 3 months

Text

Did Germany’s Bitcoin sale spur the surprising detachment from stocks?

Key Points

Germany transferred 700 Bitcoin, sparking market uncertainty due to the unmarked receiving address.

Correlation between Bitcoin and traditional investments declined, with Bitcoin price movements becoming more independent.

The German government recently transferred 700 Bitcoin (BTC), as reported by blockchain data analysis firm Arkham. This move caused some unease in the crypto market due to the destination being an unmarked address.

Germany’s Bitcoin Move

The transaction, worth roughly $40.55 million, has raised questions regarding its purpose. The receiving address could be linked to a financial institution or an over-the-counter (OTC) service that caters to large investors trading substantial volumes of cryptocurrency.

Germany currently holds about 39,826 BTC, valued at approximately $2.31 billion. This significant holding indicates a potential long-term strategy for the German government concerning cryptocurrency. The mystery surrounding the recent transfer has led to speculation of a possible large sell-off by the German government, which could cause investors to unload their holdings to avoid a potential price drop.

Decline in Correlation

Simultaneously, the correlation between Bitcoin and traditional stock markets has significantly weakened. This shift means that Bitcoin’s price movements are becoming less dependent on the fluctuations of equities, a stark contrast to previous years. This decline in correlation is the strongest it has been in over four and a half years.

Analyst Will Clemente suggests this could be due to an excess supply of Bitcoin in the market. This oversupply is believed to come from various sources, including Germany, the United States, and Mt. Gox, a now-defunct Bitcoin exchange. This excess supply is exerting downward pressure on Bitcoin’s price, independent of the stock market’s performance.

At the time of writing, BTC was trading at $57,482.70, with a 1.42% increase in the last 24 hours. However, the volume of BTC traded had declined by 47.14% during the same period.

0 notes

rushikeshmmr · 3 months

Text

Weight Management Breakthroughs: Advancements in Anti-Obesity Medications

Anti-Obesity Drugs Market Overview

Maximize Market Research is a Business Consultancy Firm that has published a detailed analysis of the “ Anti-Obesity Drugs Market”. The report includes key business insights, demand analysis, pricing analysis, and competitive landscape. The report provides the current state of the Anti-Obesity Drugs market by thorough analysis, and projections are made up to 2030.

for sample copy-https://www.maximizemarketresearch.com/request-sample/100768/

Anti-Obesity Drugs Market Scope and Methodology:

The report uses both qualitative and quantitative data to give a thorough grasp of the specifics of the Anti-Obesity Drugs market. A bottom-up methodology was employed to estimate the Anti-Obesity Drugs market. Techniques for collecting primary and secondary data were employed in order to obtain the information required for the study. The primary method uses a number of tools for gathering data, such as surveys and questionnaires. Apart from for-profit resources such as Bloomberg News and the database Hoovers for information gathering, secondary sources encompass articles, official publications, and yearly reports. In order to assess the market projection, the study closely looks at the state of buyer direct, R&D activities, advancement, cutting-edge industry techniques, and market consolidations and acquisitions. Organizational charts, portfolios, procedures, and an essential

Anti-Obesity Drugs Market Regional Insights

It is important to have a comprehensive comprehension of local perspectives in order to grasp the complex dynamics of the Anti-Obesity Drugs market. The Anti-Obesity Drugs market is divided into several regions, such as North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. A thorough examination of the variables, market size, growth rate, and volume of imports and exports in each region is provided by the study. The Anti-Obesity Drugs market's present state is shown in the Regional Analysis section for each of the research's participating nations.

Anti-Obesity Drugs Market Segmentation

by Mechanism of Action

Peripherally Acting Drugs Centrally Acting Drugs by Drug Type

Prescription Drugs OTC Drugs by Distribution Channel

Hospitals Pharmacies Retail Pharmacies E-commerce

for sample copy- https://www.maximizemarketresearch.com/request-sample/100768/

Anti-Obesity Drugs Market Key Players

North America 1. Icahn Enterprises 2. Pfizer 3. Orexigen Therapeutics 4. Bristol-Myers Squibb

Europe 5. Novo Nordisk 6. Roche 7. Norgine 8. GSK 9. Saniona 10. AstraZeneca 11. Hikma Pharmaceuticals

APAC 12. Eisai 13. Takeda Pharmaceutical Company 14. Sanofi India 15. Sun Pharmaceutical Industries 16. Teijin Pharma 17. Kowa 18. Cipla 19. Torrent Pharmaceuticals 20. Zydus Lifesciences 21. Glenmark Pharmaceuticals

Middle East 22. Teva Pharmaceutical Industries 23. Gulf Pharmaceutical Industries 24. Saudi Pharmaceutical Industries & Medical Appliances 25. The Jordanian Pharmaceutical Manufacturing Company

South America 26. Eurofarma Laboratorios

Key questions answered in the Anti-Obesity Drugs Market are:

What is Anti-Obesity Drugs?

Who are the leading companies and what are their portfolios in Anti-Obesity Drugs Market?

What growth strategies are the players considering to increase their presence in Anti-Obesity Drugs?

What are the upcoming industry applications and trends for the Anti-Obesity Drugs Market?

Which are the factors expected to drive the Anti-Obesity Drugs market growth?

What are the recent industry trends that can be implemented to generate additional revenue streams for the Anti-Obesity Drugs Market?

What was the Anti-Obesity Drugs market size in 2023?

What are the different segments of the Anti-Obesity Drugs Market?

What will be the CAGR at which the Anti-Obesity Drugs market will grow?

What is the growth rate of the Anti-Obesity Drugs Market?

What segments are covered in the Anti-Obesity Drugs Market?

What are the key challenges and opportunities in the Anti-Obesity Drugs market?

Which application holds the highest potential in the Anti-Obesity Drugs market?

Who are the key players in the Anti-Obesity Drugs market?

for sample copy-https://www.maximizemarketresearch.com/request-sample/100768/

Key Offerings:

Past Market Size and Competitive Landscape (2018 to 2022)

Past Pricing and price curve by region (2018 to 2022)

Market Size, Share, Size & Forecast by different segment | 2024−2030

Market Dynamics – Growth Drivers, Restraints, Opportunities, and Key Trends by Region

Market Segmentation – A detailed analysis by segment with their sub-segments and Region

Competitive Landscape – Profiles of selected key players by region from a strategic perspective

Competitive landscape – Market Leaders, Market Followers, Regional player

Competitive benchmarking of key players by region

PESTLE Analysis

PORTER’s analysis

Value chain and supply chain analysis

Legal Aspects of Business by Region

Lucrative business opportunities with SWOT analysis

Recommendations

About Maximize Market Research:

Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

[email protected]

+91 96071 95908, +91 9607365656

#Anti-Obesity Drugs Market Anti-Obesity Drugs Market size Anti-Obesity Drugs indusrty

0 notes